- $36.71bn
- $43.10bn
- $9.89bn
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Factbox: Global healthcare companies invest billions to boost US presence
Brief: Biogen Says Litifilimab Safety Profile Consistent With No New Safety Signals Identified
Biogen's experimental lupus drug shows benefit against skin symptoms
Corrected: UPDATE 3-Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)
US FDA approves Scholar Rock's muscle weakness drug
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
Factbox: Global drugmakers invest billions to boost US presence
Factbox: Global drugmakers invest billions to boost US presence
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Biogen beats quarterly estimates as newer drugs drive growth (updated)
Biogen Inc reports results for the quarter ended June 30 - Earnings Summary
Biogen Q2 revenue beats expectations on strong product demand
Biogen beats quarterly estimates as newer drugs fuel growth
U.S. STOCKS ON THE MOVE-Bank of America, Analog Devices, Newmont
U.S. STOCKS ON THE MOVE-Bank of America, Analog Devices, Newmont
Biogen falls as experimental Alzheimer's drug misses main trial goal